Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate
- 1 January 2001
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 26 (1) , 27-29
- https://doi.org/10.1046/j.1365-2230.2001.00753.x
Abstract
Plaques of psoriasis contain increased levels of cytokines, including tumour necrosis factor-alpha (TNF-α), which are thought to be essential to the maintenance of the psoriatic process. We report the successful treatment of severe, recalcitrant psoriasis when infliximab (a monoclonal antibody to TNF-α) was used in combination with methotrexate.Keywords
This publication has 11 references indexed in Scilit:
- Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialThe Lancet, 2000
- Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJournal of the American Academy of Dermatology, 2000
- The Salford Psoriasis Index: an holistic measure of psoriasis severityBritish Journal of Dermatology, 2000
- Cytokine Blockade as a New Strategy to Treat Rheumatoid ArthritisArchives of internal medicine (1960), 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- The Majority of Epidermal T Cells in Psoriasis Vulgaris Lesions can Produce Type 1 Cytokines, Interferon-γ, Interleukin-2, and Tumor Necrosis Factor-α, Defining TC1 (Cytotoxic T Lymphocyte) and TH1 Effector Populations:1 a Type 1 Differentiation Bias is also Measured in Circulating Blood T Cells in Psoriatic PatientsJournal of Investigative Dermatology, 1999
- Review article: safety of infliximab in clinical trialsAlimentary Pharmacology & Therapeutics, 1999
- Introduction: anti-TNF strategies in the treatment of Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 1999
- Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesionsClinical and Experimental Immunology, 1994
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978